Cidara Therapeutics Inc Stock
-
Your prediction
Cidara Therapeutics Inc Stock
Pros and Cons of Cidara Therapeutics Inc in the next few years
Pros
Cons
Performance of Cidara Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | - | - | - | - | - | - | - |
| Vaxart Inc. | -0.740% | -2.857% | -3.478% | -69.558% | -2.857% | -70.531% | -94.963% |
| Larimar Therapeutics Inc. | -2.080% | -15.663% | -10.256% | -29.648% | -15.663% | -25.134% | -84.036% |
| aTyr Pharma Inc | -2.730% | -8.333% | -9.836% | -86.041% | -8.333% | -76.066% | -81.908% |
Comments
News
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
According to a November 14, 2025 SEC filing, HighVista Strategies LLC initiated a new stake in Cidara Therapeutics (NASDAQ:CDTX), acquiring 70,904 shares worth $6.79 million as of September 30
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics (NASDAQ:CDTX), increasing its position value by approximately $167.48
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
Just prior to last week's takeover news, Cidara Therapeutics (NASDAQ: CDTX) was already one of the year's top-performing stocks. Trading in the mid-$20s at the start of 2025, by mid-November, this



